Results 31 to 40 of about 3,819 (202)
Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
Case Reports in Neurology, 2016 Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of ...
Valentin Held +3 more
doaj +1 more source
Journal of Medical Case Reports, 2019 Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani +3 more
doaj +1 more source
Managing patients taking novel oral anticoagulants (NOAs) in dentistry: A discussion paper on clinical implications [PDF]
, 2016 Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors ...
Costantinides, Fulvia +3 more
core +1 more source
TH Open, 2019 Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery.
Nicolas Gendron +5 more
doaj +1 more source
Frontiers in Neurology, 2019 We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery following the antagonization of dabigatran with idarucizumab.
Maren Hieber, Juergen Bardutzky
doaj +1 more source
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism [PDF]
, 2015 Objective To compare the safety and efficacy of dabigatran to warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Background Venous thromboembolism (VTE) is a disease comprised of two conditions: deep vein thrombosis and pulmonary
Dixon, Dave L., Ogbonna, Kelechi C.
core +3 more sources
No Benefit for Idarucizumab [PDF]
Deutsches Ärzteblatt international, 2016 The review article by Lange et al. on the management of anticoagulation in the setting of endoscopic interventions provides helpful advice and pointers for routine clinical practice (1). Their assessment clashes with the available evidence in one single issue: idarucizumab has thus far not been shown to offer any benefit in terms of the safe ...
openaire +2 more sources
Intravenous thrombolysis following dabigatran reversal in a patient with acute embolic stroke after atrial fibrillation ablation. [PDF]
J ArrhythmThis case demonstrated the feasibility of administering emergent intravenous thrombolysis followed by Dabigatran reversal with idarucizumab in a patient who underwent atrial fibrillation ablation. The consideration of transitioning anticoagulant therapy to dabigatran for scheduled AF ablation in patients at high risk of stroke should be carefully ...
Chen YS, Lin CY.
europepmc +2 more sources
Direkt orális antikoagulánsok a kardiológiában | Direct oral anticoagulants in cardiology [PDF]
, 2016 Absztrakt Az antithromboticus gyógyszeres kezelés napjaink gyakorlati medicinájának egyik fontos, de sokszor bizony eléggé faragatlan talpköve.
Kiss, Róbert Gábor
core +1 more source
Trauma Case Reports, 2018 Introduction: Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding,
Gail Edwards +3 more
doaj +1 more source